DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* BIOMÉTHODES *


 

1997 - IDF
Évry
(near Paris)
www.biomethodes.com

 

Contract, Manufacturing
(also Design, Drugs)
Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme
Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics
Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food
info@biomethodes.com

Age: 19 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio]
Sc.Dir.-CSO: Winter (Bruno) [Ph.D., ex-AB Enzymes]
Techn.Dir.-CTO: Langvad (Niels) [ex-Biodiesel (co-founder)]
Fin.Dir.-CFO: Kazandjian (Raffy) [ex-CDC-Innovation Partners]
BusDev:
Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC)

Turnover (M€) : 0.009 (2009), 0.75 (2008), 0.25 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Haemophilia
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .10 Financing (no interest loan) : 0.7 M€, by OSEO, for the development and industrialization of enzymes DEBT [13 years]
2011 .03 Set-up of OptaFuel US, based in Abingdon, Virginia, with plans to build a pilot plant ORGC [13 years]
2008 .06 Licensing-in of processes of biomass to bioethanol and biohydrogen from Virginia Tech Intellectual Properties (USA) LICIN [10 years]
2007 .12 Patent : granted on Massive Mutagenesis LEGAL [10 years]
2007 .11 Nomination : Gilles Amsallem as CEO [ex-Finance Director], taking over from founder Marc Delcourt (as CSO, first, then leaving to found Global Bioenergiesin 2008) ORGN [9 years]
2006 .02 Partnering research agreement with Sanofi-Aventis to develop Solexis, a new technology R&D [8 years]
2004 .05 Licensing-out of Massive Mutagenesis to Aventis Pharma for R&D optimization LICOUT [6 years]
2003 .10 2nd round-financing : 4.5 M€, by CDC Innovation, CIC Capital, FCJE (CDC) RFINB [5 years]
1997 .11 Company founded by Marc Delcourt ORGF [0 year]

Actualisation / Updating: 27-Oct-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende